HEMO CHINA was present at CSA & TISC 2021, this year’s edition of the Annual Scientific Session of Chinese Stroke Association (CSA) and Tiantan International Stroke Conference (TISC). At the symposium, HEMO CHINA also marked the commercial launch of its Afentta™ and FocuStar™ products with a series of academic promotion activities.
HEMO BIOENGINEERING LIMITED (“HEMO”), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy aspiration catheter – a product developed by HEMO’s branch in China – has received pre-market approval from the National Medical Products Administration (“NMPA”), becoming the first approved domestic product of …
HEMO Receives NMPA Approval for Afentta™ Aspiration Catheter Read More »
Big congratulations go to our HEMO CHINA subsidiary for being recognized as the 18th Top Medical Device Company in this year’s prestigious Future Healthcare VB100 Conference. This is a spectacular jump from a year ago when HEMO was barely known then. Big thanks also go to all our supporters, partners, stakeholders, clients and employees.
enquire@hemocorp.com
